The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +2.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANVS advanced for three days, in 192 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANVS as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ANVS turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 43 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ANVS entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.630) is normal, around the industry mean (2.978). P/E Ratio (-0.549) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ANVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Aroon Indicator for VANI entered a downward trend on September 24, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 182 similar instances where the Aroon Indicator formed such a pattern. In 157 of the 182 cases the stock moved lower. This puts the odds of a downward move at 86%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VANI as a result. In 74 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for VANI turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 42 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VANI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where VANI advanced for three days, in 158 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
VANI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. VANI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.327) is normal, around the industry mean (2.978). P/E Ratio (-3.111) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VANI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ANVS | VANI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 50 | 50 | |
P/E GROWTH RATING 1..100 | 12 | 24 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANVS's Valuation (12) in the null industry is somewhat better than the same rating for VANI (69). This means that ANVS’s stock grew somewhat faster than VANI’s over the last 12 months.
ANVS's Profit vs Risk Rating (100) in the null industry is in the same range as VANI (100). This means that ANVS’s stock grew similarly to VANI’s over the last 12 months.
ANVS's SMR Rating (100) in the null industry is in the same range as VANI (100). This means that ANVS’s stock grew similarly to VANI’s over the last 12 months.
ANVS's Price Growth Rating (50) in the null industry is in the same range as VANI (50). This means that ANVS’s stock grew similarly to VANI’s over the last 12 months.
ANVS's P/E Growth Rating (12) in the null industry is in the same range as VANI (24). This means that ANVS’s stock grew similarly to VANI’s over the last 12 months.
| ANVS | VANI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 81% |
| Advances ODDS (%) | 16 days ago 79% | 14 days ago 76% |
| Declines ODDS (%) | 2 days ago 90% | 5 days ago 85% |
| BollingerBands ODDS (%) | N/A | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANVS’s FA Score shows that 2 FA rating(s) are green while VANI’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANVS’s TA Score shows that 3 TA indicator(s) are bullish while VANI’s TA Score has 4 bullish TA indicator(s).
ANVS (@Biotechnology) experienced а -7.71% price change this week, while VANI (@Biotechnology) price change was -5.08% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
ANVS is expected to report earnings on Nov 11, 2026.
VANI is expected to report earnings on Nov 18, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CET | 56.27 | 0.42 | +0.75% |
| Central Securities Corp | |||
| ESGG | 236.44 | N/A | N/A |
| Northern Trust STOXX Global ESG Select ETF (ESGG) | |||
| BSR | 30.56 | N/A | N/A |
| Beacon Unified Catalyst ETF (BSR) | |||
| HPI | 13.35 | -0.07 | -0.52% |
| John Hancock Preferred Income Fund | |||
| SBB | 23.82 | -0.32 | -1.33% |
| ProShares Short SmallCap600 (SBB) | |||
A.I.dvisor indicates that over the last year, ANVS has been loosely correlated with ADXN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ANVS jumps, then ADXN could also see price increases.
| Ticker / NAME | Correlation To ANVS | 1D Price Change % | ||
|---|---|---|---|---|
| ANVS | 100% | +1.91% | ||
| ADXN - ANVS | 43% Loosely correlated | +3.04% | ||
| JAZZ - ANVS | 38% Loosely correlated | +2.56% | ||
| DMAC - ANVS | 37% Loosely correlated | +10.17% | ||
| MDGL - ANVS | 36% Loosely correlated | +4.57% | ||
| AMLX - ANVS | 34% Loosely correlated | +5.27% | ||
More | ||||
A.I.dvisor indicates that over the last year, VANI has been loosely correlated with VTVT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if VANI jumps, then VTVT could also see price increases.
| Ticker / NAME | Correlation To VANI | 1D Price Change % | ||
|---|---|---|---|---|
| VANI | 100% | N/A | ||
| VTVT - VANI | 60% Loosely correlated | +3.36% | ||
| ADIL - VANI | 37% Loosely correlated | +7.61% | ||
| AXSM - VANI | 36% Loosely correlated | +2.42% | ||
| SCNI - VANI | 34% Loosely correlated | -9.16% | ||
| ANVS - VANI | 33% Poorly correlated | +1.91% | ||
More | ||||